Drug or intervention
Vehicle Clinical Trials
Studies that test Vehicle, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 227Sjögren's Syndrome
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
rhPRG4-Sjögren's-002 is a prospective multi-center study conducted in Australia to evaluate the safety and efficacy of topically-applied rhPRG4 in subjects with Sjögren's related Dry Eye Disease.
- Trial name
- NCT07118241
- Testing
- Recombinant Human Proteoglycan 4, Vehicle Control
- Where
- 7 sites in Australia
- Volunteers
- 80 people
- Sponsor
- Lubris Bio Pty Ltd
Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19).
- Conditions
- Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT04545762
- Testing
- Fludarabine, Cyclophosphamide, anti-CD19 CAR-T cells
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- C. Babis Andreadis
Ocular Graft Versus Host Disease
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)
An 84-day, prospective, randomized (1:1) vehicle controlled, double-masked pre-market, crossover study. Subjects with moderate to severe oGVHD related Dry Eye Disease Each subject will receive both treatments in random sequence…
- Trial name
- NCT07118254
- Testing
- rhPRG4 450ug/ml, Vehicle Control
- Where
- 3 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Lubris Bio Pty Ltd
Periodontitis, Periodontitis Stage II
Spirulina Gel in the Treatment of Periodontitis
This randomized clinical trial aims to evaluate the clinical and immunological effects of locally delivered Spirulina gel as an adjunct to scaling and root planing (SRP) in patients with Stage II, Grade B periodontitis.
- Trial name
- non (NCT07893587)
- Testing
- spirulina gel exracted by 1.5% calcium chloride (CaCl2) aqueous solution., scaling and root planing
- Volunteers
- 20 people
- Sponsor
- Misr University for Science and Technology
Viral Diseases
Effects of Food Intake on Biomarker Activity in Normal Humans Taking Immulina
The need for a generally available product that can safely and effectively increase antiviral resilience in susceptible populations became highly relevant during the recent COVID pandemic.
- Trial name
- NCT07893314
- Testing
- Immulina
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University of Mississippi Medical Center
Dry Eye Disease (DED)
An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease
This is a Phase 2, randomized, multicenter, double masked, vehicle controlled, parallel group study to evaluate the efficacy and safety of DFL24498 topical ophthalmic solution versus vehicle in participants with dry eye disease.
- Trial name
- NCT07503886
- Testing
- DFL24498, Vehicle
- Where
- 24 sites in United States
- Volunteers
- 417 people
- Sponsor
- Dompé Farmaceutici S.p.A
Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa
A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study
This is a Phase 2, double-blind, randomized, vehicle-controlled study designed to evaluate efficacy, safety, and tolerability of topically applied TCP-25 gel in patients with confirmed DEB or JEB.
- Conditions
- Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
- Trial name
- STEP (NCT06594393)
- Testing
- TCP-25 gel
- Where
- 13 sites in United States, France and 5 more
- Volunteers
- 32 people
- Sponsor
- Xinnate AB
Androgenetic Alopecia
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
The study is designed to validate efficacy and long term safety of PP405.
- Trial name
- AWAKEN (NCT07819435)
- Testing
- PP405 0.05% Topical Gel, Vehicle Topical Gel
- Where
- 63 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Pelage Pharmaceuticals, Inc.
Healthy
A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults
A study to learn how different preparations of osivelotor taste and enter the blood with food or liquids, or with an antacid in healthy adults.
- Trial name
- NCT06507904
- Testing
- Osivelotor, Famotidine
- Where
- Belgium
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Pfizer
Persistent Corneal Epithelial Defect
A Study to Evaluate the Efficacy and Safety of TP-06 for PCED
Capellion is a Phase 2 trial comparing TP-06 2.0% with Vehicle in up to 32 adults with persistent corneal epithelial defects. Participants will receive treatment for 8 weeks and be followed for 2 additional weeks to assess…
- Trial name
- Capellion (NCT07886268)
- Testing
- TP-06, Vehicle of TP-06
- Where
- 14 sites in United States, Dominican Republic and 2 more
- Volunteers
- 32 people
- Sponsor
- Tarsus Pharmaceuticals, Inc.
Completed, with results posted
All 1,024Mesopic Vision, Night Vision Loss
Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances
Safety and efficacy of 0.75% Phentolamine Ophthalmic Solution to improve mesopic low contrast visual acuity in subjects with post-refractive surgery visual disturbances.
- Trial name
- LYNX-2 (NCT06349759)
- Testing
- phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist
- Where
- 25 sites in United States
- Volunteers
- 200 people
- Sponsor
- Opus Genetics, Inc
Presbyopia
Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia
Safety and efficacy of POS in participants with presbyopia
- Trial name
- VEGA-3 (NCT06542497)
- Testing
- 0.75% phentolamine ophthalmic solution
- Where
- 39 sites in United States
- Volunteers
- 569 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Dry Eye Syndrome
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT02974907
- Testing
- RGN-259
- Where
- 10 sites in United States
- Volunteers
- 601 people
- Sponsor
- ReGenTree, LLC
Androgenetic Alopecia
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK.
- Trial name
- NCT06393452
- Testing
- PP405 0.05% Topical Gel, Topical Vehicle Gel
- Where
- 8 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Pelage Pharmaceuticals, Inc.
Androgenetic Alopecia
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
The purpose of this study is to characterize the safety, tolerability, and efficacy of topical SM04554 solution (0.15% and 0.25%) applied to the scalp of male subjects with Androgenetic Alopecia (AGA).
- Trial name
- NCT02275351
- Testing
- Topical SM04554 solution, Topical vehicle solution
- Where
- 24 sites in United States
- Volunteers
- 302 people
- Sponsor
- Biosplice Therapeutics, Inc.